Geriatric chronic kidney disease patients benefit from SGLT2 inhibition
New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2026 October 22–25.
Read original article on The Medical News →Related news
-
One in three young adults turns to AI for substance use
United Kingdom
-
Airborne ESKAPE bacteria pose severe risks to immunocompromised patients
United Kingdom
-
Next generation KRAS inhibitor divarasib significantly extends lung cancer survival
United Kingdom
-
Phase 3 EMT2 trial demonstrates survival benefit for high-dose EPA
United Kingdom
-
Substance use driving increases in emergency department visits, hospitalizations for young mothers
United Kingdom
-
A simple liquid can stop cavities without drilling, major study confirms
United States
-
Can happy feelings trigger eating too? Researchers explored both sides of emotional eating
United Kingdom
-
Beer, wine or spirits: A large study finds different mortality patterns for each
United Kingdom